Design: Cost-effectiveness analysis alongside a randomised trial (SUGAR-DIP)
Population: 820 women with gestational diabetes, 25 Dutch hospitals
Primary outcome: Costs, QALYs and large-for-gestational-age avoided
Effect: QALY +0.009 (0.004 to 0.014); societal cost −€1,004 (−€3,503 to €1,495), not significant

The SUGAR-DIP trial randomised 820 Dutch women with gestational diabetes needing drug treatment to sequential oral agents — metformin, with glibenclamide added if needed — or to insulin. This economic analysis ran alongside the trial from a societal and healthcare perspective.

Oral agents produced a slightly higher quality-adjusted life-year total (0.009, 95% CI 0.004 to 0.014), about three days of perfect health. Costs did not differ significantly (mean −€1,004, 95% CI −€3,503 to €1,495), nor did large-for-gestational-age babies avoided (−0.039, 95% CI −0.097 to 0.018). Oral agents had a 79% probability of being cost-effective even at a willingness-to-pay of zero.

The practical reading is that an oral-first strategy is not a false economy. The small trend toward more large-for-gestational-age babies with oral agents is the trade-off to discuss with the woman. In Indian practice, where insulin storage, injection teaching and glucometer supplies add real cost, the case for metformin first may be stronger still, though no Indian cost data were analysed.

Offer metformin first when diet fails, with insulin as the fallback; this analysis does not argue against it
Discuss the possible small rise in large-for-gestational-age babies with oral agents
Escalate to insulin promptly when glucose targets are not met on oral treatment
Factor in injection teaching, storage and monitoring costs when counselling on insulin

Why it matters

Removes cost as an argument against starting oral agents before insulin.

The statistics, in plain English

The QALY gain is statistically significant but tiny — about three days — so it is not clinically meaningful. The cost and large-for-gestational-age differences have confidence intervals crossing zero, meaning the trial cannot say whether either strategy is truly cheaper or better for birthweight.